Drug-induced lupus erythematosus epidemiology and demographics: Difference between revisions
No edit summary |
Jose Loyola (talk | contribs) |
||
| (13 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Drug-induced lupus erythematosus}} | {{Drug-induced lupus erythematosus}} | ||
{{CMG}}; {{AE}} {{CZ}} | |||
{{CMG}}; | |||
==Overview== | ==Overview== | ||
| Line 8: | Line 7: | ||
==Prevalence== | ==Prevalence== | ||
*In the U.S.: As many as 10% of the approximately 500,000 cases of SLE may be DIL. | *In the U.S.: As many as 10% of the approximately 500,000 cases of SLE may be DIL. | ||
*It is estimated that 6 to 12% of all [[SLE]] cases are of drug-induced lupus type. The incidence has been reported to be of 15,000 to 30,000 per year in the U.S..<ref name="pmid28722919">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume= | issue= | pages= | pmid=28722919 | doi= | pmc= | url= }} </ref> | |||
==Case-Fatality Rate== | |||
* There is no information about case-fatality rate on drug-induced lupus, but it can be potentially fatal. 16466117 <ref name="pmid16466117">{{cite journal| author=Finks SW, Finks AL, Self TH| title=Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. | journal=South Med J | year= 2006 | volume= 99 | issue= 1 | pages= 18-22 | pmid=16466117 | doi=10.1097/01.smj.0000197121.12352.19 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16466117 }} </ref> | |||
==Age== | ==Age== | ||
| Line 20: | Line 23: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Needs Overview]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 16:05, 2 November 2021
|
Drug-induced lupus erythematosus Microchapters |
|
Differentiating Drug-induced lupus erythematosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Drug-induced lupus erythematosus epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Drug-induced lupus erythematosus epidemiology and demographics |
|
FDA on Drug-induced lupus erythematosus epidemiology and demographics |
|
CDC on Drug-induced lupus erythematosus epidemiology and demographics |
|
Drug-induced lupus erythematosus epidemiology and demographics in the news |
|
Blogs on Drug-induced lupus erythematosus epidemiology and demographics |
|
Directions to Hospitals Treating Drug-induced lupus erythematosus |
|
Risk calculators and risk factors for Drug-induced lupus erythematosus epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Prevalence
- In the U.S.: As many as 10% of the approximately 500,000 cases of SLE may be DIL.
- It is estimated that 6 to 12% of all SLE cases are of drug-induced lupus type. The incidence has been reported to be of 15,000 to 30,000 per year in the U.S..[1]
Case-Fatality Rate
- There is no information about case-fatality rate on drug-induced lupus, but it can be potentially fatal. 16466117 [2]
Age
Patients with DILE tend to be older (50–70 years old) than those with SLE (average age 29 years at diagnosis). Elderly persons generally are more susceptible to DILE.
Gender
In DIL, no significant statistical difference is apparent in the prevalence for males versus females. In contrast, SLE affects women with considerably higher frequency than men (female-to-male ratio of 9:1).
Ethnicity
More whites than blacks develop DIL; more blacks than whites present with SLE.
References
- ↑ "StatPearls". 2021. PMID 28722919.
- ↑ Finks SW, Finks AL, Self TH (2006). "Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure". South Med J. 99 (1): 18–22. doi:10.1097/01.smj.0000197121.12352.19. PMID 16466117.